Kangmei Pharma | 600518 - Selling And Administration Expenses


Kangmei Pharma reported CNY237.06M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Genomma Lab Internacional MXN 1.7B 114.59M Mar/2026
Hypermarcas BRL 554.5M 201.69M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Jiangsu Hengrui CNY 2.81B 191.05M Mar/2026
Kangmei Pharma CNY 237.06M 37.35M Mar/2026
Moderna USD 173M 135M Mar/2026
Organon & Co USD 424M 9M Mar/2026
Revvity USD 253.88M 2.15M Mar/2026
Sh Fosun Pharma CNY 3.27B 1.17B Mar/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Viatris USD 928.8M 101.9M Mar/2026
Wuxi Apptec CNY 891.8M 147.89M Mar/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026
Zz Pientze Pharmaceu CNY 214.31M 42.4M Mar/2026